This article presents . We will follow a hypothetical but representative IgG1 monoclonal antibody—let us call it "Mab-X"—through the four critical stages of bioprocess development: upstream processing (cell culture), downstream processing (purification), formulation, and scale-up. By examining the specific bottlenecks, optimization strategies, and analytical milestones of Mab-X, we will illustrate why bioprocess development is often the rate-limiting step in bringing lifesaving medicines to patients.
Product development begins with the , which outlines the desired clinical safety and efficacy. From this, scientists identify Critical Quality Attributes (CQAs) —physical, chemical, or biological properties that must be within an appropriate limit to ensure product quality. A Mab A Case Study In Bioprocess Development